Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Autoimmune Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD25/IL-2RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD25/IL-2RA ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD25 Products |
| Gene Delivery | CD25/IL-2RA ORF Lentivirus Full-length ORF for stable cell line construction. Internalization assay ready. |
View CD25 Products |
| Benchmark Ab | Anti-CD25 (Basiliximab/Daclizumab Sequence) Recombinant positive control for blocking and binding assays. |
View CD25 Products |
| Validator | CD25/IL-2RA siRNA Set For knockdown verification and specificity controls. |
View CD25 Products |
| Related Target: IL-2RB | CD122 (IL-2 Receptor Beta Chain) Essential for trimeric IL-2 receptor complex formation. Cross-screening required. |
View IL2RB Products |
| Related Target: IL-2RG | CD132 (Common Gamma Chain) Shared subunit for IL-2, IL-4, IL-7, IL-15 signaling. Critical for selectivity assays. |
View IL2RG Products |
| Related Target: CTLA4 | Key regulatory T cell (Treg) marker and synergistic checkpoint target. | View CTLA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Treg vs. Effector T Cell Epitope Mapping | High-purity CD25 ECD-Fc with validated conformational integrity for competitive binding studies vs. clinical benchmark. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno CD25 ortholog proteins available with >95% purity; Sequence Verified for epitope conservation analysis. |
| Internalization Efficiency (ADC Development) | Full-length CD25 lentivirus for stable cell lines; Preserves native endocytosis kinetics for ADC payload delivery validation. |
| Soluble vs. Membrane-Bound Discrimination | ECD-Fc format captures shed extracellular domain; Lentivirus system expresses membrane-anchored form for comparative assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included; Validated siRNA for specificity checks in functional assays. |
Live CD25/IL-2RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ IL2RA Specific Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The CD25/IL-2RA therapeutic landscape is bifurcating into two distinct strategic directions: Treg depletion for immuno-oncology (via ADCC-enhanced antibodies or ADCs) versus Treg preservation/expansion for autoimmune indications (ultra-low dose IL-2 or non-depleting antibodies). As first-generation depleting agents face cytokine sink challenges from soluble CD25, next-generation R&D focuses on epitope-engineered antibodies that bypass the soluble receptor while maintaining high affinity for membrane-bound targets on regulatory T cells. Major players include Roche, Genentech, Bristol Myers Squibb, AstraZeneca, ADC Therapeutics, Novartis, Sanofi, and Amgen. The pipeline is shifting from traditional immunosuppressive mAbs to complex oncology modalities such as ADCs and engineered cytokines (IL-2 variants).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Depleting mAb (ADCC+) | Roche, Genentech, Bristol Myers Squibb | Solid Tumors (Treg depletion) | ADCC Reporter Assay; Need high-purity CD25 expressing target cells via lentivirus stable lines |
| ADC | AstraZeneca, ADC Therapeutics, Genmab | Hematologic Malignancies, Hodgkin Lymphoma | Internalization Assay; Need pH-sensitive binding validation using ECD-Fc fusion proteins |
| Non-depleting Antagonist | Novartis, Sanofi | Multiple Sclerosis, Uveitis, Transplant | IL-2 Blocking Assay; Competition ELISA with Basiliximab benchmark antibody |
| IL-2 Muteins (Engineered Cytokines) | Amgen, Sanofi, Roche, Alkermes | Type 1 Diabetes, SLE, Advanced Solid Tumors | Selectivity Assay; CD25+ cells vs. CD122/CD132 intermediate affinity complex discrimination |
| Bispecific (Treg Engager/Depleter) | Tusk Therapeutics (Roche), BioAlta, Biotech startups | Autoimmune Diseases, Immunotherapy Combinations | Heterodimer Validation; Cross-reactive Abs for human/cyno bridging studies |
| CAR-T / Cell Therapy | Various Academic / Biotech | T-Cell Lymphomas | Target recognition; Need Native Glycosylated HEK293 Expressed Antigens |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Epitope Engineering: For tumor depletion, antibodies should target membrane-proximal epitopes not exposed on soluble CD25 to avoid cytokine sink. For autoimmune protection, epitopes overlapping with IL-2 binding site are needed for complete blockade without triggering Treg death.
- Affinity & PK: Moderate affinity (Kd ~1-10 nM) may be optimal for solid tumor penetration. pH-dependent binding (dissociation at pH 6.0, binding at pH 7.4) can enhance ADC efficacy by promoting receptor recycling.
- Cross-species Reactivity: Human/Cyno CD25 conservation is ~95%, but key epitope differences exist (e.g., Basiliximab does not bind mouse CD25). TarMart provides Human/Mouse/Cyno orthologs for bridging studies.
- Subfamily Selectivity: CD25 shares structural similarity with IL-15Rα and shares CD122/CD132 subunits. Antibodies must be validated for no cross-reactivity with IL-15Rα using TarMart's IL-2RB and IL-2RG proteins.
Core Assay Development Roadmap
| Development Stage | Key Assay | Technical Specification | TarMart Product Application |
|---|---|---|---|
| Early Screening | IL-2 Neutralization Blocking Assay | IC50 determination vs. Basiliximab | CD25 ECD-Fc as coating antigen; Basiliximab as positive control |
| Functional Validation | Treg Suppression Recovery | In vitro Treg:Teff co-culture system | Lentivirus for stable CD25-overexpressing T cell lines |
| ADCC Development | Effector Cell Killing | ADCC Reporter Bioassay | High-purity CD25 lentivirus-transfected CHO-K1 target cells |
| ADC Optimization | Internalization Rate | pHAb dye or MabTx assay | Membrane-bound CD25 cell model (Lentivirus constructed) |
| Safety | Off-target Screening | Cross-reactivity with IL-15Rα, IL-4R, IL-7R | IL2RB and IL2RG recombinant proteins for specificity validation |
| PK/PD | Receptor Occupancy (RO) | Flow cytometry | Anti-CD25 antibody as detection reagent; CD25 protein as standard |
Strategic Cross-sell Targets
Based on IL-2/IL-15 signaling pathway complexity and combination therapy trends, the following related targets are recommended for cross-selling:
- CD122 (IL-2RB): Shared subunit for IL-2 and IL-15 receptors. Essential for dual blockade strategies and bispecific antibody screening.
- CD132 (IL-2RG, Common Gamma Chain): Shared by IL-2, IL-4, IL-7, IL-15, IL-21. Used as selectivity control for CD25 antibody validation panels.
- CTLA4: Key Treg marker and synergistic checkpoint target for combination therapies.
- FOXP3: Intracellular Treg lineage-specific transcription factor. Used for validating Treg functional status changes after CD25-targeted therapy.